新型 HIV-1 治愈潜伏逆转剂
Novel Latency Reversal Agents for HIV-1 Cure.
机构信息
Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84112.
Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah 84112; email:
出版信息
Annu Rev Med. 2018 Jan 29;69:421-436. doi: 10.1146/annurev-med-052716-031710. Epub 2017 Nov 3.
Abstract
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.
摘要
抗逆转录病毒疗法（ART）使 HIV-1 感染成为一种可治疗的疾病；然而，由于复制能力强的潜伏前病毒在长寿静止 T 细胞中持续存在，ART 并不能治愈。为了在感染个体中根除 HIV-1，需要针对这些潜伏感染的细胞的策略，以允许免疫识别和清除这个储库。这篇综述描述了目前药理学方法来重新激活潜伏储库，以便可以识别和靶向受感染的细胞，最终目标是实现 HIV-1 的治愈。
相似文献
1
Novel Latency Reversal Agents for HIV-1 Cure.新型 HIV-1 治愈潜伏逆转剂
Annu Rev Med. 2018 Jan 29;69:421-436. doi: 10.1146/annurev-med-052716-031710. Epub 2017 Nov 3.
2
Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.合成 Ingenols 最大限度地提高蛋白激酶 C 诱导的 HIV-1 潜伏期逆转。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01361-18. Print 2018 Nov.
3
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.马拉维若与潜伏 HIV-1 再激活有关，通过抑制性抗逆转录病毒治疗的 HIV 感染者静息 CD4 T 细胞中 NF-κB 的激活。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01931-17. Print 2018 May 1.
4
Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.1类选择性组蛋白去乙酰化酶（HDAC）抑制剂增强HIV潜伏逆转，同时保留最大HIV基因表达所需的HDAC亚型的活性。
J Virol. 2018 Feb 26;92(6). doi: 10.1128/JVI.02110-17. Print 2018 Mar 15.
5
Clinical Interventions in HIV Cure Research.HIV 治愈研究中的临床干预措施。
Adv Exp Med Biol. 2018;1075:285-318. doi: 10.1007/978-981-13-0484-2_12.
6
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.帕比司他对细胞相关HIV RNA和DNA水平及潜伏性HIV感染影响的体内分析。
Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.
7
Latency Reversal 2.0: Giving the Immune System a Seat at the Table.潜伏期逆转 2.0：让免疫系统参与其中。
Curr HIV/AIDS Rep. 2021 Apr;18(2):117-127. doi: 10.1007/s11904-020-00540-z. Epub 2021 Jan 12.
8
Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.潜伏 HIV-1 前病毒的 NF-κB 非依赖性信号再激活。
J Virol. 2019 Aug 28;93(18). doi: 10.1128/JVI.00495-19. Print 2019 Sep 15.
9
Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.激活潜伏的 HIV-1 T 细胞储库的组合：先天免疫和表观遗传调节剂。
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01194-19. Print 2019 Nov 1.
10
A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.一种新型喹啉类 BRD4 抑制剂，针对潜伏 HIV-1 储库的另一个不同靶点，可被其他“休克”药物激活。
J Virol. 2018 Apr 27;92(10). doi: 10.1128/JVI.02056-17. Print 2018 May 15.
引用本文的文献
1
Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.“乘客”假说在HIV病毒库持久性及治愈方面的应用与局限性
J Virol. 2025 Jul 22;99(7):e0071425. doi: 10.1128/jvi.00714-25. Epub 2025 Jun 4.
2
Neuroinflammation, Blood-Brain Barrier, and HIV Reservoirs in the CNS: An In-Depth Exploration of Latency Mechanisms and Emerging Therapeutic Strategies.中枢神经系统中的神经炎症、血脑屏障与HIV储存库：潜伏期机制及新兴治疗策略的深入探索
Viruses. 2025 Apr 16;17(4):572. doi: 10.3390/v17040572.
3
GS143, an inhibitor of E3 ligase β-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFκB.GS143是一种E3连接酶β-TrCP的抑制剂，它通过非传统激活NFκB逆转HIV-1潜伏状态，而不激活T细胞。
PLoS Pathog. 2025 Apr 1;21(4):e1013018. doi: 10.1371/journal.ppat.1013018. eCollection 2025 Apr.
4
Neuropathogenesis of acute HIV: mechanisms, biomarkers, and therapeutic approaches.急性HIV的神经发病机制：机制、生物标志物及治疗方法
Curr Opin HIV AIDS. 2025 May 1;20(3):199-208. doi: 10.1097/COH.0000000000000923. Epub 2025 Mar 26.
5
ISG15-LFA1 interactions in latent HIV clearance: mechanistic implications in designing antiviral therapies.ISG15与LFA1相互作用在潜伏性HIV清除中的作用：对抗病毒疗法设计的机制启示
Front Cell Dev Biol. 2024 Dec 24;12:1497964. doi: 10.3389/fcell.2024.1497964. eCollection 2024.
6
Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice.双价SMAC模拟物APG-1387可减少人源化小鼠体内的HIV储存库并限制病毒反弹。
iScience. 2024 Nov 27;27(12):111470. doi: 10.1016/j.isci.2024.111470. eCollection 2024 Dec 20.
7
The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review.遗传多样性、表观遗传调控及性别差异在HIV治愈研究中的作用：一项综述
Epigenetics Chromatin. 2025 Jan 3;18(1):1. doi: 10.1186/s13072-024-00564-4.
8
Exploring potential associations between the human microbiota and reservoir of latent HIV.探索人类微生物组与潜伏 HIV 储库之间的潜在关联。
Retrovirology. 2024 Nov 29;21(1):21. doi: 10.1186/s12977-024-00655-w.
9
NSC95397 Is a Novel HIV-1 Latency-Reversing Agent.NSC95397 是一种新型的 HIV-1 潜伏逆转剂。
Viruses. 2024 Nov 16;16(11):1783. doi: 10.3390/v16111783.
10
Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.海洋蓝细菌：用于药物开发的结构独特抗感染药物的丰富来源。
Molecules. 2024 Nov 10;29(22):5307. doi: 10.3390/molecules29225307.
本文引用的文献
1
HIV persistence in macrophages.HIV在巨噬细胞中的持续存在。
Nat Med. 2017 May 5;23(5):538-539. doi: 10.1038/nm.4337.
2
The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.Ingenol-B对精英抑制性HIV特异性CD8+ T细胞抑制能力的影响。
PLoS One. 2017 May 3;12(5):e0174516. doi: 10.1371/journal.pone.0174516. eCollection 2017.
3
Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.苯并三唑通过使信号转导和转录激活因子5（STAT5）的SUMO化失活来重新激活潜伏的HIV-1。
Cell Rep. 2017 Jan 31;18(5):1324-1334. doi: 10.1016/j.celrep.2017.01.022.
4
Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.雷帕霉素介导的mTOR抑制作用将HIV-1潜伏激活与细胞因子相关毒性分离开来。
J Clin Invest. 2017 Feb 1;127(2):651-656. doi: 10.1172/JCI89552. Epub 2017 Jan 17.
5
Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.Janus激酶抑制可抑制蛋白激酶C诱导的细胞因子释放，而不影响离体条件下HIV-1潜伏状态的逆转。
Retrovirology. 2016 Dec 20;13(1):88. doi: 10.1186/s12977-016-0319-0.
6
HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.HIV-1潜伏逆转剂原锥虫素和苔藓抑素-1可导致血脑屏障破坏/炎症，并调节白细胞黏附/迁移。
J Immunol. 2017 Feb 1;198(3):1229-1241. doi: 10.4049/jimmunol.1600742. Epub 2016 Dec 19.
7
The mTOR Complex Controls HIV Latency.mTOR复合物控制HIV潜伏。
Cell Host Microbe. 2016 Dec 14;20(6):785-797. doi: 10.1016/j.chom.2016.11.001.
8
Euphorbia Kansui Reactivates Latent HIV.甘遂可重新激活潜伏的艾滋病毒。
PLoS One. 2016 Dec 15;11(12):e0168027. doi: 10.1371/journal.pone.0168027. eCollection 2016.
9
In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.小分子蛋白激酶 C 激动剂对 HIV 潜伏期再激活的体外作用。
Sci Rep. 2016 Dec 12;6:39032. doi: 10.1038/srep39032.
10
Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.Toll样受体8激动剂与原苏木素协同激活潜伏HIV的潜在作用。
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.02084-16. Print 2017 Feb 15.
Zotero 插件